Pharmaceutical - Pharmaceutical, Dainippon Sumitomo Pharma

Filter

Popular Filters

1 to 25 of 32 results

Sumitomo Dainippon to halve its Japanese production sites

Sumitomo Dainippon to halve its Japanese production sites

29-12-2014

Japanese pharma company Sumitomo Dainippon is to reduce its four production sites in Japan to just two.

Dainippon Sumitomo PharmaJapanPharmaceuticalProductionSumitomo

Most-used agents in US bipolar disorder treatment sector; report

Most-used agents in US bipolar disorder treatment sector; report

24-10-2014

Through analysis of US longitudinal patient-level claims data, Bristol-Myers Squibb and Otsuka’s Abilify…

AbilifyBristol-Myers SquibbCymbaltaDainippon Sumitomo PharmaEli LillyGlaxoSmithKlineLamotrigineLatudaMarkets & MarketingNeurologicalOtsukaPharmaceuticalUSA

Latuda’s arrival better late than never for schizophrenia treatment in the UK, says analyst

12-09-2014

The recent introduction of antipsychotic drug Latuda (lurasidone) into the UK market, three years after…

Dainippon Sumitomo PharmaHealthcareLatudaMarkets & MarketingNeurologicalPharmaceuticalSunovion PharmaceuticalsUK

Canadian approval for Sunovion’s Aptiom

Canadian approval for Sunovion’s Aptiom

14-07-2014

USA-based drugmaker Sunovion Pharmaceuticals, a subsidiary of Japan’s Dainippon Sumitomo, has received…

AptiomBIA-2093-301CanadaDainippon Sumitomo PharmaEpilepsyNeurologicalPharmaceuticalRegulationSunovion Pharmaceuticals

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

Dainippon Sumitomo and Daiichi Sankyo cooperate on lurasidone in South America

28-05-2014

Japanese drug majors Dainippon Sumitomo Pharma and Daiichi Sankyo have entered into a license agreement…

ArgentinaBrazilDaiichi SankyoDainippon Sumitomo PharmaLicensinglurasidoneNeurologicalPharmaceuticalSouth AmericaVenezuela

US FDA calls for lower starting dose for sleep drug Lunesta

16-05-2014

The US Food and Drug Administration says it has required the manufacturer of the sleep drug Lunesta (eszopiclone)…

Dainippon Sumitomo PharmaLunestaNeurologicalPharmaceuticalRegulationSunovion PharmaceuticalsUSA

Sunovion’s once-daily epilepsy drug Aptiom debuts in USA

08-04-2014

USA-based Sunovion Pharmaceuticals, a subsidiary of Japanese drug major Dainippon Sumitomo, has launched…

AptiomDainippon Sumitomo PharmaMarkets & MarketingNeurologicalNorth AmericaPharmaceuticalSunovionUSA

EU approval for Dainippon Sumitomo and Takeda’s Latuda

EU approval for Dainippon Sumitomo and Takeda’s Latuda

28-03-2014

Japanese drug majors Dainippon Sumitomo Pharma and Takeda Pharmaceutical have received European Commission…

Dainippon Sumitomo PharmaEuropeLatudaNeurologicalPharmaceuticalRegulationSunovionTakeda Pharmaceuticals

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

Edison Pharma in deal with Dainippon Sumitomo potentially worth $4.3 billion

31-01-2014

Privately-held US company Edison Pharmaceuticals has entered into a new strategic alliance valued up…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589LicensingMetabolicsNeurologicalPharmaceutical

Intercept rockets on positive liver disease drug trial

10-01-2014

Shares of USA-based Intercept Pharmaceuticals tripled to $275.87 by close of trading on January 9, when…

Dainippon Sumitomo PharmaIntercept PharmaceuticalsNephrology and Hepatologyobeticholic acidPharmaceuticalResearch

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

FDA thumbs up for Sunovion’s Aptiom as once-daily adjunctive for partial-onset seizures

09-11-2013

The US Food and Drug Administration on Friday approved Sunovion Pharmaceutical’s (a subsidiary of Japanese…

AptiomDainippon Sumitomo PharmaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

15-10-2013

Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical’s atypical antipsychotic Latuda (lurasidone)…

Dainippon Sumitomo PharmaGlobalLatudaMarkets & MarketingNeurologicalPharmaceuticalTakeda Pharmaceuticals

Sunovion's eslicarbazepine successful in Ph III epilepsy studies

18-09-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

Dainippon Sumitomo PharmaeslicarbazepineNeurologicalPharmaceuticalResearchSunovion

Takeda gains first European approval for lurasidone

14-08-2013

Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

Sunovion announces novel drug discovery partnership

14-08-2013

Sunovion Pharmaceuticals, a wholly-owned US subsidiary of Japanese drug major Dainippon Sumitomo Pharma…

AfraxisDainippon Sumitomo PharmaLicensingNeurologicalPharmaceuticalResearchSunovion

Dainippon Sumitomo establishes regenerative and cellular medicine office

12-08-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says that it has set up the Regenerative &…

Asia-PacificBiotechnologyDainippon Sumitomo PharmaPharmaceuticalProductionResearch

Top-line financials for Japanese drug majors

01-08-2013

Among a flurry of first-quarter fiscal 2013/14 financial results released by Japanese drug majors, the…

Dainippon Sumitomo PharmaEisaiFinancialMitsubishi TanabePharmaceuticalTakeda Pharmaceuticals

US District Court issues final judgment in favor of Mylan in Brovana patent dispute

09-07-2013

US generics and specialty drugmaker Mylan (Nasdaq: MYL) revealed yesterday (July 8) that the US District…

BrovanaDainippon Sumitomo PharmaGenericsLegalMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalRespiratory and PulmonarySunovion

US FDA backs news indications for Latuda; grants Priority Review for Perjeta

02-07-2013

Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Top-line financial results from Japanese drug majors

09-05-2013

Among a batch of Japanese drug majors presenting fiscal year 2013 (ended April 2013) financial results,…

Dainippon Sumitomo PharmaFinancialMitsubishi TanabePharmaceuticalShionogiTakeda Pharmaceuticals

Dainippon Sumitomo gains rights to Edison Pharma drug candidates in up to $545 million accord

02-04-2013

Privately-held US firm Edison Pharmaceuticals has entered into a research, development and commercialization…

Dainippon Sumitomo PharmaEdison PharmaceuticalsEPI-589EPI-743LicensingNeurologicalPharmaceuticalResearch

Dainippon Sumitomo partners with Nippon Shinyaku for urology drug AMP-986

12-03-2013

Japanese drugmakers Dainippon Sumitomo Pharma (TYO: 4506) and Nippon Shinyaku (TYO: 4516) have concluded…

AMP-986Asia-PacificDainippon Sumitomo PharmaGenito-urinaryLicensingNippon ShinyakuPharmaceutical

Dainippon Sumitomo sets up subsidiary in Singapore

21-01-2013

Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) has established a wholly-owned subsidiary in…

Asia-PacificDainippon Sumitomo PharmaMarkets & MarketingPharmaceuticalSunovion

Japanese approvals for Eylea, Tresiba, Seebri and Aimix

01-10-2012

There was a flurry of announcements from Japan's Ministry of Health, Labor and Welfare (MHLW) on Friday,…

AimixAsia-PacificBayerCardio-vascularDainippon Sumitomo PharmaDiabetesEyleaNovartisNovo NordiskOphthalmicsPharmaceuticalRegeneronRegulationRespiratory and PulmonarySeebri BreezhalerShionogiTresibaVectura

1 to 25 of 32 results

COMPANY SPOTLIGHT

Menarini

Back to top